학술논문
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
Document Type
Journal Article
Author
Palich, Romain; Allavena, Clotilde; Peytavin, Gilles; Soulie, Cathia; Tubiana, Roland; Weiss, Laurence; Ferrer, Ana Montoya; Duvivier, Claudine; Bouchaud, Olivier; Bottero, Julie; Durand, Aurore; Lê, Minh-Patrick; Marcelin, Anne-Geneviève; Dudoit, Yasmine; Assoumou, Lambert; Katlama, Christine; group, the ETRAL QD study; Montoya Ferrer, Ana; ETRAL QD study group (CORPORATE AUTHOR)
Source
Subject
*RALTEGRAVIR
*HIV-positive persons
*TERMINATION of treatment
*PATIENTS' attitudes
*CD4 lymphocyte count
*HIV
*PNEUMOCYSTIS jiroveci
*
*
*
*
*
*
Language
ISSN
0305-7453
Abstract